Maybe the tunable CAR-Ts of ZIOP will work. In theory, it should minimize problems with the constitutive CAR-Ts. In seems like the problems with constitutive CAR-Ts should have been anticipated, and brilliant minds should have designed tunable promoters right away and not even waste resources on constitutive CAR-Ts.
There is no good data yet on how well ADCs will work for solid tumors. I'm starting to doubt how great Kadcyla is for BC. Maybe ADCs might be more effective against solid tumors if used with HALO's hyaluronidase.
I've been waiting to add except that it is about time for equity offering. This takes away people's immediate concern about the need for that stock offering. Back to $6 tomorrow. It would be nice if it touches or passes the 52-week high.